English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Although diabetes is a major risk factor for ischemic heart disease or heart failure (HF), and despite the fact that echocardiography has revealed a high prevalence of left ventricular (LV) diastolic and systolic dysfunctions and hypertrophy (1–3), routine screening for cardiovascular disease using echocardiography in asymptomatic patients with type 2 diabetes is not recommended by current guidelines (4). The availability of laboratory markers of cardiovascular risk would substantially contribute to the early and simple screening of patients at increased risk of HF, allowing them to be better targeted with appropriate pharmacological therapies (5). As part of the LV Dysfunction in Diabetes (DYDA) study, we assessed the relations between different laboratory markers, including centrally assayed glycated hemoglobin (HbA1c), N-terminal probrain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), …

Cardiovascular Biomarkers, Cardiac Dysfunction, and Outcomes in Patients With Type 2 Diabetes: A Prospective, Multicenter Study